[1] |
中国抗癌协会.中国恶性肿瘤整合诊治指南: 胆囊癌[J].肿瘤, 2022,42(3): 188-202.DOI: 10.3781/j.issn.1000-7431.2022.2112-0938.Association CA.Chinese guidelines for integrated diagnosis and treatment of malignant tumors: gallbladder cancer[J].Tumor, 2022,42(3): 188-202.DOI: 10.3781/j.issn.1000-7431.2022.2112-0938.
|
[2] |
中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会.胆囊癌诊断和治疗指南(2019版)[J].中华外科杂志, 2020, 58(4): 243-251.DOI: 10.3760/cma.j.cn112139-20200106-00014.Branch of Biliary Surgery of Chinese Surgery Society of Chinese Medical Association, Chinese Medical Doctor Association in Chinese Committee of Biliary Surgeons.Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)[J].Chin J Surg,2020, 58(4): 243-251.DOI: 10.3760/cma.j.cn112139-20200106-00014.
|
[3] |
Benson AB, D’Angelica MI, Abrams T, et al.NCCN guidelines®insights: biliary tract cancers, version 2.2023[J].J Natl Compr Canc Netw, 2023, 21(7): 694-704.DOI: 10.6004/jnccn.2023.0035.
|
[4] |
Rebholz C, Krawczyk M, Lammert F.Genetics of gallstone disease[J].Eur J Clin Invest, 2018, 48(7): e12935.DOI: 10.1111/eci.12935.
|
[5] |
Di Ciaula A, Garruti G, Frühbeck G, et al.The role of diet in the pathogenesis of cholesterol gallstones[J].Curr Med Chem, 2019,26(19): 3620-3638.DOI: 10.2174/0929867324666170530080636.
|
[6] |
Yang P, Javle M, Pang F, et al.Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients[J].Hepatobiliary Surg Nutr, 2019, 8(6): 604-614.DOI: 10.21037/hbsn.2019.04.11.
|
[7] |
Roa J, García P, Kapoor VK, et al.Gallbladder cancer[J].Nat Rev Dis Primers, 2022, 8(1): 69.DOI: 10.1038/s41572-022-00398-y.
|
[8] |
Doherty G, Manktelow M, Skelly B, et al.The need for standardizing diagnosis, treatment and clinical care of cholecystitis and biliary colic in gallbladder disease[J].Medicina, 2022, 58(3): 388.DOI: 10.3390/medicina58030388.
|
[9] |
Lammert F, Gurusamy K, Ko CW, et al.Gallstones[J].Nat Rev Dis Primers, 2016, 2: 16024.DOI: 10.1038/nrdp.2016.24.
|
[10] |
Fukumura Y, Rong L, Maimaitiaili Y, et al.Precursor lesions of gallbladder carcinoma: disease concept, pathology, and genetics[J].Diagnostics, 2022, 12(2): 341.DOI: 10.3390/diagnostics12020341.
|
[11] |
Iyer P, Barreto SG, Sahoo B, et al.Non-typhoidal Salmonella DNA traces in gallbladder cancer[J].Infect Agent Cancer, 2016, 11: 12.DOI: 10.1186/s13027-016-0057-x.
|
[12] |
Hemminki K, Försti A, Hemminki O, et al.Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast[J].Int J Cancer, 2022, 151(2): 200-208.DOI: 10.1002/ijc.33980.
|
[13] |
Muraki T, Pehlivanoglu B, Memis B, et al.Pancreatobiliary maljunction-associated gallbladder cancer is as common in the west, shows distinct clinicopathologic characteristics and offers an invaluable model for anatomy-induced reflux-associated physiochemical carcinogenesis[J].Ann Surg, 2022, 276(1): e32-e39.DOI:10.1097/SLA.0000000000004482.
|
[14] |
Abdel-Wahab R, Yap TA, Madison R, et al.Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer[J].Sci Rep, 2020, 10(1): 22087.DOI: 10.1038/s41598-020-77939-6.
|
[15] |
Ebata N, Fujita M, Sasagawa S, et al.Molecular classification and tumor microenvironment characterization of gallbladder cancer by comprehensive genomic and transcriptomic analysis[J].Cancers,2021, 13(4): 733.DOI: 10.3390/cancers13040733.
|
[16] |
Javle M, Rashid A, Churi C, et al.Molecular characterization of gallbladder cancer using somatic mutation profiling[J].Hum Pathol,2014, 45(4): 701-708.DOI: 10.1016/j.humpath.2013.11.001.
|
[17] |
Roessler S, Edeline J, Schirmacher P, et al.Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer[J].J Hepatol, 2021, 74(5):1018-1020.DOI: 10.1016/j.jhep.2020.12.024.
|
[18] |
Nepal C, Zhu B, O’Rourke CJ, et al.Integrative molecular characterisation of gallbladder cancer reveals micro-environmentassociated subtypes[J].J Hepatol, 2021, 74(5): 1132-1144.DOI:10.1016/j.jhep.2020.11.033.
|
[19] |
Zhang Y, Zuo C, Liu L, et al.Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer[J].J Hepatol, 2021, 75(5): 1128-1141.DOI: 10.1016/j.jhep.2021.06.023.
|
[20] |
Chen P, Wang Y, Li J, et al.Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single-cell RNA sequencing[J].Clin Transl Med, 2021, 11(6): e462.DOI: 10.1002/ctm2.462.
|
[21] |
CSCO 胆道肿瘤专家委员会.CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J].临床肿瘤学杂志, 2019, 24(9): 828-838.CSCO Committee of Experts on Biliary Tumors.Expert consensus on diagnosis and treatment of CSCO biliary systerm tumors(2019 edition)[J].Chin Clin Oncol, 2019, 24(9): 828-838.
|
[22] |
Saluja SS, Nekarakanti PK, Mishra PK, et al.Prospective randomized controlled trial comparing adjuvant chemotherapy vs.No chemotherapy for patients with carcinoma of gallbladder undergoing curative resection[J].J Gastrointest Surg, 2022, 26(2): 398-407.DOI:10.1007/s11605-021-05143-6.
|
[23] |
Seita K, Ebata T, Mizuno T, et al.Phase 2 trial of adjuvant chemotherapy with S-1 for node-positive biliary tract cancer (N-SOG 09)[J].Ann Surg Oncol, 2020, 27(7): 2348-2356.DOI: 10.1245/s10434-020-08355-3.
|
[24] |
Nakachi K, Ikeda M, Konishi M, et al.Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT):a multicentre, open-label, randomised, controlled, phase 3 trial[J].Lancet, 2023, 401(10372): 195-203.DOI: 10.1016/S0140-6736(22)02038-4.
|
[25] |
Sharma A, Mohanti BK, Chaudhary SP, et al.Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: results of a phaseⅢrandomised controlled trial[J].Eur J Cancer, 2019, 123: 162-170.DOI: 10.1016/j.ejca.2019.10.004.
|
[26] |
Roa I, de Toro G, Schalper K, et al.Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer[J].Gastrointest Cancer Res, 2014, 7(2): 42-48.
|
[27] |
Lee CK, Chon HJ, Cheon J, et al.Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)[J].Lancet Gastroenterol Hepatol, 2023,8(1): 56-65.DOI: 10.1016/S2468-1253(22)00335-1.
|
[28] |
Javle M, Borad MJ, Azad NS, et al.Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre,open-label, phase 2a, multiple basket study[J].Lancet Oncol, 2021,22(9): 1290-1300.DOI: 10.1016/S1470-2045(21)00336-3.
|
[29] |
Harding JJ, Fan J, Oh DY, et al.Zanidatamab for HER2-amplified,unresectable, locally advanced or metastatic biliary tract cancer(HERIZON-BTC-01): a multicentre, single-arm, phase 2b study[J].Lancet Oncol, 2023, 24(7): 772-782.DOI: 10.1016/S1470-2045(23)00242-5.
|
[30] |
Demols A, Borbath I, Van den Eynde M, et al.Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind,phaseⅡtrial[J].Ann Oncol, 2020, 31(9): 1169-1177.DOI: 10.1016/j.annonc.2020.05.018.
|
[31] |
Ikeda M, Ioka T, Fukutomi A, et al.Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine[J].Cancer Sci, 2018, 109(1): 215-224.DOI: 10.1111/cas.13438.
|
[32] |
Subbiah V, Iannotti NO, Gutierrez M, et al.FIGHT-101, a first-inhuman study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies[J].Ann Oncol, 2022, 33(5): 522-533.DOI: 10.1016/j.annonc.2022.02.001.
|
[33] |
Tan ES, Cao B, Kim J, et al.Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers[J].Cancer, 2021, 127(8): 1293-1300.DOI: 10.1002/cncr.33364.
|
[34] |
Klein O, Kee D, Nagrial A, et al.Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial[J].JAMA Oncol, 2020, 6(9): 1405-1409.DOI: 10.1001/jamaoncol.2020.2814.
|
[35] |
Ueno M, Ikeda M, Morizane C, et al.Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised,multicentre, open-label, phase 1 study[J].Lancet Gastroenterol Hepatol, 2019, 4(8): 611-621.DOI: 10.1016/S2468-1253(19)30086-X.
|
[36] |
Oh DY, He AR, Bouattour M, et al.Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study[J].Lancet Gastroenterol Hepatol,2024,9(8):694-704.DOI: 10.1016/S2468-1253(24)00095-5.
|
[37] |
Kelley RK, Ueno M, Yoo C, et al.Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966):a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2023, 401(10391): 1853-1865.DOI: 10.1016/S0140-6736(23)00727-4.
|
[38] |
Guo Y, Feng K, Liu Y, et al.Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers[J].Clin Cancer Res, 2018, 24(6): 1277-1286.DOI: 10.1158/1078-0432.CCR-17-0432.
|
[39] |
闫甲,刘双池,王政宇.胆囊癌肿瘤标志物的研究和应用进展[J].中华普通外科学文献(电子版),2023,17(5):391-394.DOI: 10.3877/cma.j.issn.1674-0793.2023.05.015.Yan J, Liu SC, Wang ZY.Progress in the reasearch and application of tumor markers for gallbladder cancer[J/OL].Chin Arch Gen Surg(Electron Ed), 2023, 17(5): 391-394.DOI: 10.3877/cma.j.issn.1674-0793.2023.05.015.
|
[40] |
Rimini M, Fornaro L, Lonardi S, et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data[J].Liver Int, 2023, 43(8): 1803-1812.DOI:10.1111/liv.15641.
|